RIN2

Across TCGA pan-cancer cohorts, RIN2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RIN2 data layer compared with 26 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RIN2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RIN2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where RIN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.413	0.665	<.001	39	view →
LSCC	DFS	Quartile	II,III,IV	0.474	0.890	.004	8	view →
LUAD	OS	Tertile	III,IV	0.787	0.242	.016	6	view →
CCRCC	OS	Median	IV	1.000	0.202	.034	4	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RIN2–PDAC (OS)

Open the PDAC breakdown →